Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2596 | Non-Anchoring Strategy Control Wiki | 1.00 |
| drug3372 | Rintatolimod Wiki | 1.00 |
| drug3286 | Recombinant Interferon Alfa-2b Wiki | 1.00 |
Navigate: Correlations HPO
There is one clinical trial.
The purpose of the study is to optimize the delivery of mHealth tools to support the formation of persistent mindfulness meditation routines. Aim 1: Identify the efficacy of the anchoring strategy on the persistence of daily meditation practice. H1: Persistence (measured through repeated observations of panel regression models of the daily likelihood of mindfulness mediation over the 16-week follow-up period) will be greater among AG as compared to CG. Aim 2: Determine participant phenotypes that are (a) associated with successfully anchoring daily meditation or (b) likely to need additional supports. Potential moderators of the anchoring strategy's success include participants' daily schedule, type of work, household composition, motivation, time and risk preferences, and prior exposure to mindfulness, which will be analyzed in the panel regression model framework above. Aim 3: Determine the optimal type, timing, and sequence of push notifications for encouraging daily mindfulness meditation within and across study groups. The efficacy of each push notification type (tracking sessions completed, reminders, mood symptom tracking, and group-specific goal reminders), timing, and dynamics on the anchoring of daily meditation will inform a subsequent, just-in-time adaptive intervention (JITAI). Impact: This study will inform an optimal JITAI R01 proposal that will personalize the type and temporal dynamics of app-based daily supports for successfully routinizing daily meditation, and determine its effects on mental health, specifically PTSD. Lifetime prevalence of PTSD is 7% in adults and meditation is known to reduce PTSD. If effective
Description: Acceptability will be measured using a satisfaction survey at the end of the study, following all other measures (satisfied with the intervention and perceive daily meditation and app components as appropriate and useful)
Measure: Feasibility: Acceptability Time: Measured at post-intervention about experience in study (8 weeks) and follow up (16 weeks)Description: Demand will be measured using objective app usage data provided by the Calm app informatics. Data will be on individual app feature(s) used, time of day the app/feature was used, and time spent in meditation.
Measure: Feasibility 2: Demand Time: Measured at post-intervention about experience in study (8 weeks) and follow up (16 weeks)Description: Stress will be measured using the Perceived Stress Scale -10 item, with scores ranging from 10-40) and a higher score indicates a worse outcome.
Measure: Stress Time: Change from baseline (week 0) to post-intervention (week 8) to follow up (week 16)Description: Anxiety will be measured using the Hospital Anxiety and Depression Scale, with scores ranging from 0-21, and a higher score indicates a worse outcome.
Measure: Anxiety Time: Change from baseline (week 0) to post-intervention (week 8) to follow up (week 16)Description: Depression will be measured using the Hospital Anxiety and Depression Scale, with scores ranging from 0-21, and a higher score indicates a worse outcome.
Measure: Depression Time: Change from baseline (week 0) to post-intervention (week 8) to follow up (week 16)Description: Global health will be measured using the PROMIS Global Health Scale v1.2, with scores ranging from 4-20, and higher scores indicate a better outcome.
Measure: Global Health Time: Change from baseline (week 0) to post-intervention (week 8) to follow up (week 16)Description: PTSD will be measured using the Impact of Events Scale-Revised, with scores ranging from 0-88, with higher scores indicating a worse outcome.
Measure: PTSD Time: Change from baseline (week 0) to post-intervention (week 8) to follow up (week 16)Description: Emotional regulation will be measured using the Difficulties in Emotional Regulation -18, with scores ranging from 18-90, with higher scores indicating a worse outcome.
Measure: Emotional Regulation Time: Change from baseline (week 0) to post-intervention (week 8) to follow up (week 16)Description: Habit will be measured using the habit questionnaire scored is the sum across the four questions (which are individually scored from 1-5 based on degree of agreement), where a higher score indicates more behavioral automaticity (strong habit).
Measure: HABIT Time: Change from baseline (week 0) to post-intervention (week 8) to follow up (week 16)Description: COVID-19 as a mediator to the other health and well-being measures will be measured through a COVID-19 questionnaire created by the researcher.
Measure: COVID-19 Time: Change from baseline (week 0) to post-intervention (week 8) to follow up (week 16)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports